Individuals Stopping Slimming Jabs Put On Weight Far More Rapidly Compared to People Using Diet and Exercise

A recent study indicates that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds much more quickly than those who end traditional lifestyle programs.

Findings released in a leading medical journal shows that while obese people can lose a large proportion of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.

"Users using such drugs must be aware of the danger of fast weight regain when the medication ends," cautioned lead investigator Dr. Susan Jebb.

That rate of regain means a return to starting weight within about 18 months.

Weighing Therapies

The study, which reviewed dozens of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with conventional dieting.

Researchers note that people who shed pounds through lifestyle changes alone typically have a less rapid creep back—around 0.1 kg a month—post-intervention.

The Reason for the Rapid Rebound

Doctors believe the mechanism of the drugs is key to understanding the accelerated weight return.

These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.

"Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to produce less of its own natural hormone, and may also lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' results in appetite is no longer kept in check, making binge eating a significant risk."

A Chronic Issue?

Medical guidelines recommend the injections for individuals with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.

Many experts contend that, considering the likelihood of weight regain, the treatment might need to be life-long.

This view is reinforced by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," similar to managing diseases like diabetes.

Patient Accounts

Users who have come off the medication explain a sudden resurgence of cravings.

"It felt as if something activating and you're instantly extremely hungry," recalled a patient.

This difficulty is compounded if users have not established permanent dietary or behavioural modifications during therapy.

Widespread Interest

Recent estimates suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.

• Use is higher among women than males.
• The 40s and 50s age group shows the highest level of interest.
• Many access the medications through private prescriptions rather than public health services.

Ultimately, experts stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone fix and maintained weight loss likely depends on combined lifestyle changes.